Cellromax Science (A471820) Stock Overview
Focuses to merge with other companies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
A471820 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cellromax Science Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,280.00 |
| 52 Week High | ₩7,690.00 |
| 52 Week Low | ₩4,560.00 |
| Beta | 0 |
| 1 Month Change | 5.18% |
| 3 Month Change | 5.39% |
| 1 Year Change | 3.13% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -33.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| A471820 | KR Capital Markets | KR Market | |
|---|---|---|---|
| 7D | -2.2% | 0.4% | 4.3% |
| 1Y | 3.1% | 217.7% | 143.2% |
Return vs Industry: A471820 underperformed the KR Capital Markets industry which returned 218.5% over the past year.
Return vs Market: A471820 underperformed the KR Market which returned 143.4% over the past year.
Price Volatility
| A471820 volatility | |
|---|---|
| A471820 Average Weekly Movement | 5.0% |
| Capital Markets Industry Average Movement | 10.8% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in KR Market | 16.1% |
| 10% least volatile stocks in KR Market | 4.7% |
Stable Share Price: A471820 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A471820's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | n/a | n/a | hanwha-plus-no3spac.com |
Cellromax Science Co., Ltd. focuses to merge with other companies. The company was founded in 2022 and is based in Seoul, South Korea.
Cellromax Science Co., Ltd. Fundamentals Summary
| A471820 fundamental statistics | |
|---|---|
| Market cap | ₩58.07b |
| Earnings (TTM) | ₩2.97b |
| Revenue (TTM) | ₩22.18b |
Is A471820 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A471820 income statement (TTM) | |
|---|---|
| Revenue | ₩22.18b |
| Cost of Revenue | ₩11.64b |
| Gross Profit | ₩10.55b |
| Other Expenses | ₩7.58b |
| Earnings | ₩2.97b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 268.68 |
| Gross Margin | 47.54% |
| Net Profit Margin | 13.37% |
| Debt/Equity Ratio | 0% |
How did A471820 perform over the long term?
See historical performance and comparisonDividends
Does A471820 pay a reliable dividends?
See A471820 dividend history and benchmarks| Cellromax Science dividend dates | |
|---|---|
| Ex Dividend Date | Mar 30 2026 |
| Dividend Pay Date | May 15 2026 |
| Days until Ex dividend | 28 days |
| Days until Dividend pay date | 18 days |
Does A471820 pay a reliable dividends?
See A471820 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/27 08:38 |
| End of Day Share Price | 2026/04/27 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cellromax Science Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.